NamiRNA-enhancer network of miR-492 activates the NR2C1-TGF-β/Smad3 pathway to promote epithelial-mesenchymal transition of pancreatic cancer
Carcinogenesis · 2023
DOI: 10.1093/carcin/bgac102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, 2023. Verfasst von Shanshan Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Scientific research Center, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang road, Jinshan District, Shanghai 201508, China. Hauptthemen laut MEDLINE: MicroRNAs, Pancreatic Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai, Shanghai Public Health Clinical Center.
Abstract (Originalsprache)
Pancreatic cancer (PaCa) is one of the most fatal malignancies of the digestive system, and most patients are diagnosed at advanced stages due to the lack of specific and effective tumor-related biomarkers for the early detection of PaCa. miR-492 has been found to be upregulated in PaCa tumor tissue and may serve as a potential therapeutic target. However, the molecular mechanisms by which miR-492 promotes PaCa tumor growth and progression are unclear. In this study, we first found that miR-492 in enhancer loci activated neighboring genes (NR2C1/NDUFA12/TMCC3) and promoted PaCa cell proliferation, migration, and invasion in vitro. We also observed that miR-492-activating genes significantly enriched the TGF-β/Smad3 signaling pathway in PaCa to promote epithelial-mesenchymal transition (EMT) during tumorigenesis and development. Using CRISPR–Cas9 and ChIP assays, we further observed that miR-492 acted as an enhancer trigger, and that antagomiR-492 repressed PaCa tumorigenesis in vivo, decreased the expression levels of serum TGF-β, and suppressed the EMT process by downregulating the expression of NR2C1. Our results demonstrate that miR-492, as an enhancer trigger, facilitates PaCa progression via the NR2C1-TGF-β/Smad3 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Scientific research Center, Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang road, Jinshan District, Shanghai 201508, China.
- Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Hepatobiliary Surgery, Shanghai Jiaotong University School of Medicine Xinhua Hospital, Shanghai, China.
- State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan 430062, China.
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
- Diet and Cardiovascular Health Group, Nutritional Sciences Division, King's College London, 150 Stamford Street, Waterloo, London SE19NH, UK.
ORCID-Profile: Jin Wang
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai
- Shanghai Public Health Clinical Center
- Special Research Fund of Youan Medical Alliance for the Liver and Infectious Diseases
Zitieren
APA
Liu, S., He, X., Di, Y., Li, Q., Li, F., Ma, Y., Chen, L., Gao, Y., Xu, J., Yang, S., Xu, L., Corpe, C., Ling, Y., Zhang, X., Xu, J., Yu, W., & Wang, J. (2023). NamiRNA-enhancer network of miR-492 activates the NR2C1-TGF-β/Smad3 pathway to promote epithelial-mesenchymal transition of pancreatic cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgac102
Vancouver
Liu S, He X, Di Y, Li Q, Li F, Ma Y, et al. NamiRNA-enhancer network of miR-492 activates the NR2C1-TGF-β/Smad3 pathway to promote epithelial-mesenchymal transition of pancreatic cancer. Carcinogenesis. 2023. doi:10.1093/carcin/bgac102
BibTeX
@article{Liu2023,
author = {Liu, Shanshan and He, Xiaomeng and Di, Yang and Li, Qiuyue and Li, Feng and Ma, Yan and Chen, Litian and Gao, Yushi and Xu, Jingjing and Yang, Shuai and Xu, Li and Corpe, Christopher and Ling, Yun and Zhang, Xiaoyan and Xu, Jianqing and Yu, Wenqiang and Wang, Jin},
title = {NamiRNA-enhancer network of miR-492 activates the NR2C1-TGF-β/Smad3 pathway to promote epithelial-mesenchymal transition of pancreatic cancer},
journal = {Carcinogenesis},
year = {2023},
doi = {10.1093/carcin/bgac102}
}
EUVIMED